Onpattro
Named-patient access overview. Onpattro is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Onpattro (patisiran) is a lipid nanoparticle-formulated small interfering RNA (siRNA) approved by the US Food and Drug Administration in August 2018 for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults. The product is marketed approximately by Alnylam Pharmaceuticals. Patisiran was the first FDA-approved RNA interference therapeutic, a landmark in the development of the technology. The drug is delivered by intravenous infusion every three weeks at a weight-based dose with pre-medication to manage infusion reactions.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Onpattro
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Onpattro is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Onpattro in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Onpattro
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.